Opko Health, Inc. Acquires Lead NK-1 Compounds from Schering-Plough Corporation

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Amex:OPK) today announced that it has entered into a definitive agreement with Schering-Plough Corporation (NYSE: SGP) (“Schering-Plough”) to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications. Phase 1 clinical testing has also been initiated for a second compound in the same class. It is anticipated that these compounds may have advantages over presently marketed products.

Back to news